For example, class I HDACs have been found to be overexpressed in bladder tumors [41], breast tumors [42], prostate tumors [43], and renal cells [44], and overexpression of HDAC2 and HDAC3 has also been shown to be associated with clinicopathological indicators of disease progression [42]. This evidence concerns the gene HDAC3 and prostate neoplasm.